Position in ALKS
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$6,139,415
+$5,439,665 QoQ
Shares Held
173,626
+594.5% QoQ
Ownership
0.103%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2020
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALKS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Hudson Bay Capital Management LP holds $72,604,865 across 10 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BHC |
Bausch Health Companies Inc.
|
5,000,000 | $24,650,000 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
130,000 | $21,910,200 | |
| 3 | GLAS |
Glass House Brands Inc.
|
750,000 | $9,750,000 | |
| 4 | TAK |
Takeda Pharmaceutical Co Ltd
|
275,000 | $4,408,250 | |
| 5 | BCRX |
Biocryst Pharmaceuticals Inc
|
400,000 | $4,000,000 | |
| 6 | UTHR |
UNITED THERAPEUTICS Corp
|
5,000 | $2,709,150 | |
| 7 | HIMS |
Hims & Hers Health, Inc.
|
70,009 | $2,427,211 | |
| 8 | AQST |
Aquestive Therapeutics, Inc.
|
234,000 | $973,440 |
All Filings in ALKS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,139,415 | 173,626 | Shares | Sole | 2026-05-13 | |
| 2024-09-30 | $699,750 | 25,000 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $723,000 | 30,000 | Shares | Sole | 2024-08-14 | |
| 2023-12-31 | $832,200 | 30,000 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $840,300 | 30,000 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $939,000 | 30,000 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $845,700 | 30,000 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $783,900 | 30,000 | Shares | Sole | 2023-02-14 | |
| 2020-06-30 | $1,164,600 | 60,000 | Shares | Sole | 2020-08-12 | |
| No filing history on record for this holder in this stock. | ||||||